40

Anticoagulants

40.1 ANTICOAGULANTS – CLASSIFICATION



40.2 PARENTERAL ANTICOAGULANTS – HEPARIN



40.3 ADRs AND CONTRAINDICATIONS OF HEPARIN



40.4 LOW-MOLECULAR-WEIGHT HEPARINS (LMWHs) AND HEPARIN ANTAGONIST



40.5 SYNTHETIC HEPARIN DERIVATIVES, HEPARINOIDS, AND PARENTERAL DIRECT THROMBIN INHIBITORS



40.6 ORAL ANTICOAGULANTS – MECHANISM OF ACTION AND PHARMACOKINETICS (WARFARIN)



40.7 USES AND ADRs OF WARFARIN



40.8 DRUG INTERACTIONS OF WARFARIN

** The list of drug-drug interactions & drug-food interactions with warfarin is forever, and none is mentioned in the lecture.



40.9 ORAL DIRECT THROMBIN INHIBITORS



40.10 DIFFERENCES BETWEEN HEPARIN vs. LMW HEPARIN

	Heparin	**Low-molecular-weight heparin**
1. Mol wt	High	Low
2. Source	Natural	Semi-synthetic
3. Thrombin inhibition	Present	Absent
4. Clotting parameters	Effected	Not effected
5. Laboratory monitoring	Needed	Not needed
6. SC bioavailability	Low	High
7. Duration of action	2–4 h (Short)	18–24 h (long)
8. Dose	4–6/day	Once daily
9. Bleeding complications	High	Minimal
10. Thrombocytopenia	High	Low

40.11 DIFFERENCES BETWEEN HEPARIN AND DICUMAROL/WARFARIN

	Heparin	**Dicaumarol/warfarin**
1. Source	Natural	Synthetic
2. Chemistry	Mucopolysaccharide	Coumarin
3. Action	In vitro and in vivo	Only in vivo
4. Administration	Parenteral (IV/SC)	Oral
5. Onset	Rapid (3–6 h)	Slow (1–3 days)
6. Duration	Short (2–4 h)	Long (4–7 days)
7. Mechanism	Stimulates antithrombin III	Inhibits clotting factors
8. Antidote	Protamine sulfate	Vitamin K1 oxide
9. Usage	For initiation	For maintenance
10. Usage in pregnancy	Used	Not used as it is teratogenic
11. Cost	Expensive	Economical
12. Monitoring	Measuring aPTT/clotting time	Synthetic

41

Antiplatelet agents

41.1 CLASSIFICATION AND ASPIRIN



41.2 PURINERGIC RECEPTOR (P2Y12) ANTAGONISTS/ADP ANTIGONISTS AND PHOSPHODIESTERASE (PDE) INHIBITORS



41.3 GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONISTS AND MISCELLANEOUS



41.4 USES OF ANTIPLATELET AGENTS



42

Thrombolytics (fibrinolytics) and antifibrinolytics

42.1 THROMBOLYTICS (FIBRINOLYTICS) – INTRODUCTION, CLASSIFICATION, AND INDIVIDUAL AGENTS



42.2 USES, ADRs, AND CONTRAINDICATIONS



42.3 ANTIFIBRINOLYTICS – USES AND CONTRAINDICATIONS

most details are not mentioned, only the drug's name